CN113712858B - Preparation and application of antibacterial and anti-inflammatory plant extract composition - Google Patents
Preparation and application of antibacterial and anti-inflammatory plant extract composition Download PDFInfo
- Publication number
- CN113712858B CN113712858B CN202110771103.8A CN202110771103A CN113712858B CN 113712858 B CN113712858 B CN 113712858B CN 202110771103 A CN202110771103 A CN 202110771103A CN 113712858 B CN113712858 B CN 113712858B
- Authority
- CN
- China
- Prior art keywords
- composition
- inflammatory
- chlorogenic acid
- antibacterial
- mass ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 34
- 239000000419 plant extract Substances 0.000 title claims abstract description 23
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 29
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 29
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 29
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 29
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 29
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 29
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 29
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 29
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 29
- 241001529734 Ocimum Species 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 240000004980 Rheum officinale Species 0.000 claims abstract description 17
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 17
- 241000219061 Rheum Species 0.000 claims abstract description 11
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 10
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 25
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 108010059892 Cellulase Proteins 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 239000008395 clarifying agent Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 238000001471 micro-filtration Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000014103 egg white Nutrition 0.000 claims description 2
- 210000000969 egg white Anatomy 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 13
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 231100000321 erythema Toxicity 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 240000007926 Ocimum gratissimum Species 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 4
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- -1 anthraquinone compounds Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960002504 capsaicin Drugs 0.000 description 3
- 235000017663 capsaicin Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 239000010282 Emodin Substances 0.000 description 2
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 2
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 235000011205 Ocimum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical group OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001206 effect on leukocytes Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/82—Preparation or application process involves sonication or ultrasonication
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a bacteriostatic and anti-inflammatory plant extract composition and application thereof. According to the invention, the antibacterial property and the additive amount of the composition are tested by taking the compound proportion of the basil, the chlorogenic acid and the medicinal rheum officinale as the cut-in points, and finally the plant extract composition with small additive amount and strong antibacterial and anti-inflammatory effects is obtained. Wherein, the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3), 0.05-0.2 and (1-3). The composition can effectively inhibit the breeding of skin pathogenic bacteria, and reduce inflammatory reaction by reducing active oxygen free radicals, removing inflammatory factors, improving the water loss of the horny layer and the like.
Description
Technical Field
The invention belongs to the field of cosmetics, and relates to preparation and application of a bacteriostatic and anti-inflammatory plant extract composition.
Background
Due to the continuous improvement of life style of people, the continuous change of life environment, the influence of age, psychological pressure, environmental pollution, four seasons change, chemical abuse and the like, numerous injuries are brought to skin and skin mucous membrane, and the occurrence rate of skin diseases is in a continuous rising trend. Modern medical research shows that the dysbacteriosis of human body and the breeding of pathogenic bacteria can lead to endocrine dysfunction, the reaction often causes vigorous sebum secretion on the skin, and simultaneously, the skin is complicated with inflammation, acne, pimple at the top, and the like.
Ocimum basilicum is a plant of Labiatae, ocimum, herba Achilleae, herba Pogostemonis, herba Cymbidis, and herba West king, and is a medicinal and edible aromatic plant. The flavor is similar to fennel, the whole plant is small and exquisite, the leaf color is emerald green, the color is bright, and the fragrance is overflowed. Ocimum basilicum is one of the main aromatic oil plants, and the volatile oil mainly exists in stems, leaves and flowers and ears of the Ocimum basilicum, and generally contains 0.1-0.12% of oil. The whole herb of Ocimum basilicum can be used as medicine, has the property of Wen Weixin, has various effects of dispelling wind and promoting qi, activating blood, resolving dampness, promoting digestion, removing toxin and the like, and has a sterilization rate of the pure Ocimum basilicum essential oil of hundred ninety-nine percent.
Chlorogenic acid (Chlorogenic acid) is a phenylpropionic acid substance, is an ester formed by caffeic acid and quinic acid, exists in common Chinese herbal medicines such as capillary artemisia, honeysuckle and the like, has a strong broad-spectrum antibacterial effect, and the research on the biological activity of Chlorogenic acid in modern science is deep into a plurality of fields such as food, health care, medicine, daily chemical industry and the like. Chlorogenic acid is an important bioactive substance, and has antibacterial, antiviral, leukocyte increasing, liver protecting, gallbladder function promoting, antitumor, blood pressure lowering, blood lipid reducing, free radical scavenging, and central nervous system exciting effects.
Rheum officinale (Rheum palmatum L.), rheum officinale (Rheum offcinale baill.), rheum tanguticum (Rheum tanguticum Maxim. Ex Balf.), and Rheum tanguticum (Rheum tanguticum Maxim.) are generally dry roots and rhizomes of Polygonaceae. The main functions are as follows: purging heat toxin, removing accumulation and stagnation, promoting blood stasis, etc. The anthraquinone compounds include emodin, physcion, aloe-emodin, rhein, chrysophanol, etc. The rheum officinale has a broad antibacterial spectrum, and has an inhibiting effect on a plurality of gram-positive bacteria and negative bacteria such as staphylococcus aureus, hemolytic streptococcus, typhoid bacillus, shigella dysenteriae, helicobacter pylori and the like; has inhibiting effect on various fungi, influenza virus, hepatitis virus and human immunodeficiency virus.
At present, the application of the three components of the basil, the chlorogenic acid and the rheum officinale is mainly concentrated in the fields of medicines, foods and health products, and the three components are not much applied in the field of cosmetics. The Singh S finds that the basil volatile oil has obvious inhibition effect on plantar swelling caused by carrageenan of rats and edema caused by arachidonic acid and leukotriene, and meanwhile, the basil (whole herb) extract can reduce the ear swelling degree of rats and has inhibition effect on leukocyte migration in a model of air bag inflammation of rats caused by carrageenan, so that the NO and MDA content in serum is reduced and the SOD activity is enhanced; in recent years, new antibacterial mechanisms have been reported for chlorogenic acid to act by reducing the hardness of the bacterial cell wall, slowing down bacterial migration, affecting the stability of the bacterial cell membrane and inducing the production of reactive oxygen species (reactive oxygen species, ROS); research of Agarwal SK and the like shows that the active ingredients of rhein, aloe-emodin, chrysophanol and physcion in rheum officinale have antibacterial effect on novel cryptococcus, red mud fungus, candida albicans and aspergillus fumigatus. The antibacterial effective components of rhein, emodin and aloe-emodin have the most obvious effect.
When the epidermic flora of the human body is deregulated, the breeding of pathogenic bacteria can cause inflammatory reaction of the skin, and simultaneously, the generated inflammatory factors can stimulate the skin in turn, so that active oxygen free radicals are increased, larger damage is generated, and the phenomena of acne redness, epidermic water loss and the like are generated. Therefore, on one hand, the invention can inhibit the growth of harmful bacteria by regulating the biological activity of epidermic flora, reduce the risk of skin infection, and on the other hand, can reduce inflammatory reaction by reducing active oxygen free radicals, remove inflammatory factors, improve the moisture loss of horny layer and the like.
The prior researches rarely mention the application of the three components of the basil, the chlorogenic acid and the medicinal rheum officinale in the field of cosmetics.
Disclosure of Invention
The invention aims to provide a bacteriostatic and anti-inflammatory plant extract composition and application thereof, and solves the problems in the prior art. According to the invention, the antibacterial property and the additive amount of the composition are tested by taking the compound proportion of the basil, the chlorogenic acid and the medicinal rheum officinale as the cut-in points, and finally the plant extract composition with small additive amount and strong antibacterial and anti-inflammatory effects is obtained.
Aiming at the problems existing in the technical background, the invention aims to provide a preparation method of an anti-inflammatory and antibacterial plant extract composition, which comprises the following steps:
1) Pulverizing radix et rhizoma Rhei, extracting with deionized water and cellulase, and filtering to obtain first primary filtrate;
2) Extracting fresh Luo Leqie segments with ethanol to obtain a second primary filtrate;
3) Mixing the first primary filtrate and the second primary filtrate, concentrating, diluting with water, extracting with organic phase, mixing the organic phases, and concentrating to obtain fluid extract;
4) Dissolving the fluid extract with ethanol, adding chlorogenic acid powder for dissolving, concentrating to obtain concentrated solution, and ultrafiltering to obtain the anti-inflammatory and antibacterial plant extract composition;
wherein, the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3), 0.05-0.2 and (1-3).
Preferably, the preparation method comprises the following steps:
1) Pulverizing radix et rhizoma Rhei; adding deionized water for extraction, wherein the mass ratio of the rheum officinale raw material to the deionized water is 1:20-1:50, and soaking for 1-3 hours; adding cellulase at 40-50deg.C, stirring for 20 min, heating to 40-60deg.C, microwave treating for 5-15 min, reflux extracting in ultrasonic water bath for 1-3 hr, cooling to 20-30deg.C, and filtering with 100-200 mesh gauze to obtain first primary filtrate;
2) Cutting fresh basil into 1-2cm sections according to the mass ratio, soaking the fresh basil in 3-5 times of 95% ethanol solution for 1 hour, extracting at low temperature by ultrasonic oscillation, filtering, and combining the filtrates to obtain a second primary filtrate;
3) Mixing the first primary filtrate with the second primary filtrate, concentrating under reduced pressure, adding distilled water with volume 1 time of the concentrated solution, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; repeating for 2-3 times until the extract is colorless, mixing ethyl acetate layers, and concentrating under reduced pressure to obtain fluid extract;
4) Dissolving the extract with 1-3 times of ethanol, adding chlorogenic acid powder according to mass ratio, stirring to dissolve completely; filtering, adding clarifier, standing, centrifuging for 30-60 min, and filtering with microfiltration membrane to obtain filtrate. Concentrating under reduced pressure to recover ethanol to obtain concentrated solution; filtering with ultrafiltration membrane to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is (1-3), 0.05-0.2 and (1-3).
Further preferably, the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
Further preferably, the clarifying agent in the step 4) is one or more of natural clarifying agent, chitosan, juice clarifying agent, gelatin and egg white.
Further preferably, the aperture of the microfiltration membrane in the step 4) is 0.1-1.0 μm; the aperture of the ultrafiltration membrane is 0.01-0.05 μm.
The invention also provides an anti-inflammatory and antibacterial plant extract composition, which is prepared by the preparation method;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
In certain more specific embodiments, the method of preparation is specifically:
(1) Pulverizing the rheum officinale raw material according to a mass ratio;
(2) Adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20, and soaking for 2 hours. Adding cellulase in water bath at 48 ℃, wherein the total mass of the added cellulase accounts for 10% of the total mass of the raw materials, stirring for 20 minutes, heating to 54 ℃ for microwave treatment for 10 minutes, and carrying out ultrasonic water bath reflux extraction for 3 hours;
(3) Cooling the extracting solution obtained in the step (2) to room temperature, and filtering with 200-mesh gauze to obtain primary filtrate 1;
(4) Cutting fresh basil into 1-2cm sections according to the mass ratio, soaking the fresh basil in 3 times of 95% ethanol solution for 1 hour, extracting at low temperature by ultrasonic oscillation, filtering, and combining the filtrates to obtain primary filtrate 2;
(5) Combining the filtrates of the step (3) and the step (4), and concentrating under reduced pressure in a rotary evaporator at 55deg.C to obtain fluid extract; dissolving the extract with 1 times of distilled water, and sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1:1; shaking vigorously for 3h, separating organic layer, extracting for 3 times, mixing ethyl acetate layers, concentrating under reduced pressure in rotary evaporator, recovering ethyl acetate at 35deg.C to obtain fluid extract;
(6) Dissolving the extract with 3 times of ethanol, adding chlorogenic acid powder according to the mass ratio, stirring until the chlorogenic acid powder is fully dissolved, adding a clarifying agent, standing, centrifuging for 60 minutes, and filtering with a microfiltration membrane to obtain a filtrate. Filtering, concentrating under reduced pressure to recover ethanol to obtain concentrated solution.
(7) The method is characterized in that the rotating speed in the step (5) is 8000rpm;
(8) Filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
The invention also provides application of the composition in preparation of cosmetics with anti-inflammatory and antibacterial effects.
The invention also provides a cosmetic, comprising the composition and an auxiliary agent which can be used for cosmetics.
Preferably, the composition accounts for 0.5-5% of the weight of the cosmetic.
Preferably, the cosmetic is water, emulsion, spray, cream, gel or facial mask.
The application has the following beneficial effects:
1) Can effectively inhibit the breeding of skin pathogenic bacteria, and has no influence on normal flora of skin epidermis.
2) Can reduce inflammatory reaction by reducing active oxygen free radical, scavenging inflammatory factor, improving horny layer water loss, etc.
3) Compared with the conventional antibacterial composition, the natural product is used as a raw material, so that the antibacterial composition is safer and has no irritation.
Drawings
FIG. 1 is a graph showing the effect of different compositions on IL 1-alpha secretion;
FIG. 2 is a graph showing the effect of different compositions on IL-6 secretion;
FIG. 3 is a graph showing the effect of different compositions on transdermal water loss;
FIG. 4 is a graph showing the effect of different compositions on erythema.
Detailed Description
The following will explain the embodiments of the present application in detail by way of examples, whereby the implementation process of how the present application applies technical means to solve technical problems and achieve technical effects can be fully understood and implemented accordingly.
The raw materials and equipment used in the present application are common raw materials and equipment used in the field and are commercially available products unless otherwise specified. The methods used in the present application are conventional in the art unless otherwise specified.
There are many other embodiments that can be implemented, and none of them are listed here, but the embodiments claimed in the claims of this application are all applicable.
Example 1 preparation of plant extract composition effective against inflammation and bacteriostasis
In the following examples and comparative examples of the present invention, plant extract compositions capable of effectively resisting inflammation and inhibiting bacteria were prepared by the following processes.
(1) Pulverizing the rheum officinale raw material according to a mass ratio;
(2) Adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20-1:50, and soaking for 1-3 hours. Adding cellulase in water bath at 40-50deg.C, wherein the total mass of the added cellulase accounts for 10% -20% of the total mass of the raw materials, stirring for 20 min, heating to 40-60deg.C, performing microwave treatment for 5-15 min, and reflux-extracting in ultrasonic water bath for 1-3 hr;
(3) Cooling the extract obtained in the step (2) to 20-30 ℃, and filtering with 100-200 mesh gauze to obtain primary filtrate 1;
(4) Cutting fresh basil into 1-2cm sections according to the mass ratio, soaking the fresh basil in 3-5 times of 95% ethanol solution for 1 hour, extracting at low temperature by ultrasonic oscillation, filtering, and combining the filtrates to obtain primary filtrate 2;
(5) Combining the filtrates of the step (3) and the step (4), and concentrating under reduced pressure in a rotary evaporator at 50-60deg.C to obtain fluid extract; dissolving the extract with 1 times of distilled water, and sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1:1; shaking for 2-4 hr, separating organic layer, extracting for 2-3 times until colorless, mixing ethyl acetate layers, concentrating under reduced pressure in rotary evaporator, recovering ethyl acetate at 35-50deg.C to obtain fluid extract;
(6) Dissolving the extract with 1-3 times of ethanol, adding clarifier, standing, centrifuging for 30-60 min, filtering with microfiltration membrane to obtain filtrate, and reflux extracting with 1-3 times of solution for 3-5 hr. Adding chlorogenic acid powder according to the mass ratio, and stirring until the chlorogenic acid powder is fully dissolved. Filtering, concentrating under reduced pressure to recover ethanol to obtain concentrated solution.
(7) The method is characterized in that the rotating speed in the step (5) is 5000-10000rpm;
(8) Filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
Example 2 evaluation of Compound antibacterial Effect of different proportions of compositions
(1) Pulverizing the rheum officinale raw material according to a mass ratio;
(2) Adding deionized water for extraction, wherein the mass ratio of the raw materials to the deionized water is 1:20, and soaking for 2 hours. Adding cellulase in water bath at 48 ℃, wherein the total mass of the added cellulase accounts for 10% of the total mass of the raw materials, stirring for 20 minutes, heating to 54 ℃ for microwave treatment for 10 minutes, and carrying out ultrasonic water bath reflux extraction for 3 hours;
(3) Cooling the extracting solution obtained in the step (2) to room temperature, and filtering with 200-mesh gauze to obtain primary filtrate 1;
(4) Cutting fresh basil into 1-2cm sections according to the mass ratio, soaking the fresh basil in 3 times of 95% ethanol solution for 1 hour, extracting at low temperature by ultrasonic oscillation, filtering, and combining the filtrates to obtain primary filtrate 2;
(5) Combining the filtrates of the step (3) and the step (4), and concentrating under reduced pressure in a rotary evaporator at 55deg.C to obtain fluid extract; dissolving the extract with 1 times of distilled water, and sequentially extracting with petroleum ether, chloroform and ethyl acetate at a volume ratio of 1:1; shaking vigorously for 3h, separating organic layer, extracting for 3 times, mixing ethyl acetate layers, concentrating under reduced pressure in rotary evaporator, recovering ethyl acetate at 35deg.C to obtain fluid extract;
(6) Dissolving the extract with 3 times of ethanol, adding chlorogenic acid powder according to the mass ratio, stirring until the chlorogenic acid powder is fully dissolved, adding a clarifying agent, standing, centrifuging for 60 minutes, and filtering with a microfiltration membrane to obtain a filtrate. Filtering, concentrating under reduced pressure to recover ethanol to obtain concentrated solution.
(7) The method is characterized in that the rotating speed in the step (5) is 8000rpm;
(8) Filtering the solution obtained in the step (6) by using an ultrafiltration membrane, and collecting filtrate to obtain the plant extract composition with the effects of resisting inflammation and inhibiting bacteria.
Three plant extracts were compounded in the proportions shown in Table 1 below to give compositions 1 to 15, comparative examples 1 to 3.
TABLE 1
In the composition and the comparative example, the antibacterial and repairing effect test method and the result of the antibacterial and anti-inflammatory plant extract composition are as follows:
antibacterial effect detection
The strain is selected from: staphylococcus aureus, pseudomonas aeruginosa and propionibacterium acnes; the bacterial liquid is prepared by using pseudomonas aeruginosa, staphylococcus aureus and propionibacterium acnes as the listed strains. Preparation: diluting with sterile physiological saline to about 1.0x10 5 cfu/ml～1.0x10 6 cfu/ml of bacterial suspension. The prepared bacterial suspension should be used within 2 hours or stored at 2-8 ℃ for not more than 24 hours.
And (3) antibacterial effect detection: taking the plant composition obtained in the step (8) of example 2, taking a sterile dry filter paper sheet, and dripping 20. Mu.L of the actual plant composition into each sheet. Inoculating test bacteria: taking 1mL of each test bacterial suspension, and uniformly coating the suspension on the surface of a nutrient agar culture medium; the antibacterial test sample is pasted, a bacteria-staining flat plate is pasted for each test, the filter paper sheets are 4 sheets per dish, 3 sheets are test sample sheets, and 1 sheet is a control sample sheet and is blank. The bacteria-free tweezers are used for taking a sample, the sample is attached to the surface of a flat plate, the flat plate is placed in a constant temperature incubator at 36+/-1 ℃, the result is observed after the culture is carried out for 18 hours, and the diameter of the bacteria inhibition ring is measured by a vernier caliper. The results are the average of 3 measurements.
Experimental results: the results are shown in Table 2 below, and when compositions 1-15 are compared with comparative examples 1-3, it is found that:
1) The antibacterial activity of the 3 raw materials after being compounded and combined is superior to that of a single plant;
2) The antibacterial activity corresponding to different proportions of the 3 plant compound combinations is different, and the preferred antibacterial activity is basil: chlorogenic acid: rhubarb= (1-3): 0.05-0.2): 1-3, more preferably basil: chlorogenic acid: rhubarb = 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
TABLE 2
The test results show that the compositions of test examples 1-15 have good antibacterial effects compared with the blank group, but the compositions have different proportions under the same conditions, so that the antibacterial effects on various bacteria can be influenced, and the antibacterial effects of the compositions 6, 8 and 10 are relatively good.
Example 3 detection of cellular inflammation
(1) MTT cytotoxicity test
In 96well Multiplate (burning) according to 1X10 4 The density of cells/well was inoculated with 100. Mu.L each of DMEM medium containing 10% bovine serum and keratinocytes (HaCaT), and cultured for 24 hours and then replaced with serum-free medium. Compositions 6, 8 and 10 of the above examples were added to serum-free medium, respectively, and the mixture was cultured for 24 hours after the treatment. The medium was then removed, treated with 20. Mu.L of MTT solution and allowed to react at 37℃for 2 hours. Adding 200 mu L of isopropanol into cells from which MTT solution is removed, gently shaking for 30min, completely dissolving crystalline formazan, measuring absorbance at 570nm, and calculating cell survival rate according to the following formula。
The control group was tested without the addition of sample. Cytotoxicity related results are shown in table 3 below.
TABLE 3 Table 3
(2) Inflammatory factor detection
IL 1-alpha and IL-6 are cell inflammatory factors, and detection is carried out by ELISA method. Wherein HaCat cells without any treatment were used as a blank group and Lipopolysaccharide (LPS) -induced HaCat cells were used as a model group. After stimulation of HaCat cells with 1 μg/ml LPS, 1% of compositions 6, 8, 10 were added to 12 well cell plates at 100 μl per well, at 37℃with 5% CO 2 The incubator was incubated for 72h with 3 duplicate wells per experimental group. Cell culture supernatants were collected and evaluated for anti-inflammatory efficacy by ELISA assay kit, and the results averaged. The test was as follows, taking the content detected in the blank as a reference, i.e. 100%.
The specific results are shown in FIGS. 1 and 2, FIG. 1 is the effect of different compositions on IL 1-alpha secretion; FIG. 2 is a graph showing the effect of different compositions on IL-6 secretion. The results show that the compositions 6, 8 and 10 can well inhibit the production of IL 1-alpha and IL-6 inflammatory factors after LPS stimulation, have obvious anti-inflammatory effects, and the composition 10 has the best effect.
Example 4.
In a specific embodiment, the invention provides a formula process of a mask muscle base solution capable of effectively resisting inflammation and inhibiting bacteria, wherein the specific formula is shown in the following table 4:
TABLE 4 Table 4
The extracts of claim were added to the mask base solution formulations of Table 5 below, using a formulation commonly used in the art, in an amount of 1%, to prepare mask base solution examples 1-3.
TABLE 5
| Composition 6 | Composition 8 | Composition 10 |
| Sample 1 | Sample 2 | Sample 3 |
1. Safety test (human body skin patch test)
15 healthy subjects with no history of dermatological allergy between 20 and 50 years of age were selected, and the patch method: selecting qualified plaque testers, dripping about 15 mu L of sample 1-3 into the plaque testers in a closed plaque test mode, sticking the sample on the back of a subject by using a special adhesive tape, sticking 20 plaque testers to each subject, respectively sticking the myobase fluid sample of the sample 1-3, removing the testers after 24 hours, observing skin reactions after removing the testers for 0.5, 6, 12, 24 and 48 hours, and recording the results according to skin reaction grade standards in skin care product health Specification.
Test results: the results of the human skin patch test show that all subjects pass the patch test and observe skin reactions at 0.5, 6, 12, 24 and 48 hours, wherein adverse reactions such as skin erythema, pimple and blister appear in 0 cases, which indicates that the product of the invention is safe and has no stimulation.
2. Skin moisture loss and erythema repair test
(1) Number of test persons: 45 people in total; divided into 5 groups of 9 persons each.
(2) Test site: the skin of the tested person with weak forearm flexor side;
(3) Sterilizing the part to be tested with 70% alcohol, and measuring skin color ERYTHEMA value (ERYHEMA) and TEWL value after alcohol is completely evaporated; selecting 1x 1cm at the skin with weaker forearm flexor side of the tested person 2 Is a control group (blank), a model group (0.075% capsaicin stimulation), and the rest is a test group. Wherein the test group was protected with the above preferred compositions 6, 8, 10 (20. Mu.L, 10 mg/mL), and was further stimulated with 0.075% capsaicin, and after 30min, skin color erythema value and TEWL value were measured to evaluate repair status.
The specific results are shown in fig. 3 and 4, and fig. 3 is the effect of different compositions on transdermal water loss; FIG. 4 is a graph showing the effect of different compositions on erythema.
Experimental results: the plant extract compositions are effective in alleviating the increase in percutaneous water loss (TEWL) and ERYTHEMA (ERYTHEMA) caused by capsaicin stimulation.
What is not described in detail in the present specification is common general knowledge of a person skilled in the art.
As used throughout the specification and claims, the word "comprise" is an open-ended term, and thus should be interpreted to mean "include, but not limited to. By "substantially" is meant that within an acceptable error range, a person skilled in the art is able to solve the technical problem within a certain error range, substantially achieving the technical effect.
It should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a product or system that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such product or system. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a commodity or system comprising such elements.
While the foregoing description illustrates and describes the preferred embodiments of the present application, it is to be understood that this application is not limited to the forms disclosed herein, but is not to be construed as an exclusive use of other embodiments, and is capable of many other combinations, modifications and environments, and adaptations within the scope of the inventive concept described herein, through the foregoing teachings or through the skill or knowledge of the relevant arts. And that modifications and variations which do not depart from the spirit and scope of the present invention are intended to be within the scope of the appended claims.
Claims (11)
1. The preparation method of the anti-inflammatory and antibacterial plant extract composition is characterized by comprising the following steps of:
1) Pulverizing radix et rhizoma Rhei, extracting with deionized water and cellulase, and filtering to obtain first primary filtrate;
2) Extracting fresh Luo Leqie segments with ethanol to obtain a second primary filtrate;
3) Mixing the first primary filtrate and the second primary filtrate, concentrating, diluting with water, sequentially extracting with petroleum ether, chloroform and ethyl acetate, mixing ethyl acetate layers, and concentrating to obtain fluid extract;
4) Dissolving the fluid extract with ethanol, adding chlorogenic acid powder for dissolving, concentrating to obtain concentrated solution, and ultrafiltering to obtain the anti-inflammatory and antibacterial plant extract composition;
wherein, the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
2. The method of manufacturing as claimed in claim 1, comprising the steps of:
1) Pulverizing radix et rhizoma Rhei; adding deionized water for extraction, wherein the mass ratio of the rheum officinale raw material to the deionized water is 1:20-1:50, and soaking for 1-3 hours; adding cellulase at 40-50deg.C, stirring for 20 min, heating to 40-60deg.C, microwave treating for 5-15 min, reflux extracting in ultrasonic water bath for 1-3 hr, cooling to 20-30deg.C, and filtering with 100-200 mesh gauze to obtain first primary filtrate;
2) Soaking fresh Luo Leqie with 1-2cm section in 3-5 times of 95% ethanol solution for 1 hr, extracting at low temperature by ultrasonic vibration, filtering, and mixing filtrates to obtain second primary filtrate;
3) Mixing the first primary filtrate with the second primary filtrate, concentrating under reduced pressure, adding distilled water with volume 1 time of the concentrated solution, and sequentially extracting with petroleum ether, chloroform and ethyl acetate; repeating for 2-3 times until the extract is colorless, mixing ethyl acetate layers, and concentrating under reduced pressure to obtain fluid extract;
4) Dissolving the fluid extract with 1-3 times of ethanol, adding chlorogenic acid powder according to mass ratio, stirring to dissolve completely, adding clarifier, standing, centrifuging for 30-60 min, and filtering with microfiltration membrane to obtain filtrate; concentrating under reduced pressure to recover ethanol to obtain concentrated solution; filtering with ultrafiltration membrane to obtain the plant extract composition with antiinflammatory and antibacterial effects;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
3. The method of claim 2, wherein the clarifying agent in step 4) is a natural clarifying agent.
4. The method of claim 2, wherein the clarifying agent in step 4) is a juice clarifying agent.
5. The method according to claim 2, wherein the clarifying agent in the step 4) is one or more of chitosan, gelatin and egg white.
6. The method according to claim 2, wherein the microfiltration membrane in step 4) has a pore size of 0.1 to 1.0 μm; the aperture of the ultrafiltration membrane is 0.01-0.05 μm.
7. An anti-inflammatory and bacteriostatic plant extract composition, characterized in that it is prepared by the preparation method according to any one of claims 1 to 6;
wherein the basil: chlorogenic acid: the mass ratio of the rhubarb raw materials is 1:0.2:2 or 1:0.1:2 or 1:0.1:3.
8. Use of a composition according to claim 7 for the preparation of a cosmetic product having anti-inflammatory and bacteriostatic effects.
9. A cosmetic comprising the composition of claim 7 and a cosmetically acceptable adjuvant.
10. The cosmetic according to claim 9, wherein the composition comprises 0.5 to 5% by mass of the cosmetic.
11. The cosmetic product of claim 9, wherein the cosmetic product is an aqueous solution, an emulsion, a spray, a cream, a gel, or a mask.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771103.8A CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110771103.8A CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113712858A CN113712858A (en) | 2021-11-30 |
| CN113712858B true CN113712858B (en) | 2024-02-13 |
Family
ID=78673119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110771103.8A Active CN113712858B (en) | 2021-07-07 | 2021-07-07 | Preparation and application of antibacterial and anti-inflammatory plant extract composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113712858B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961376A (en) * | 2010-07-23 | 2011-02-02 | 新疆医科大学 | Method for refining sweet basil herb extract |
| CN108308203A (en) * | 2018-01-31 | 2018-07-24 | 南京紫源康医药科技有限公司 | A kind of preparation method of Chinese medicinal compound extract, extract and bacteria inhibiting composition |
-
2021
- 2021-07-07 CN CN202110771103.8A patent/CN113712858B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961376A (en) * | 2010-07-23 | 2011-02-02 | 新疆医科大学 | Method for refining sweet basil herb extract |
| CN108308203A (en) * | 2018-01-31 | 2018-07-24 | 南京紫源康医药科技有限公司 | A kind of preparation method of Chinese medicinal compound extract, extract and bacteria inhibiting composition |
Non-Patent Citations (3)
| Title |
|---|
| 周秋丽等.现代中药基础研究与临床.天津科技翻译出版公司,2012,(第1版),第75页. * |
| 郑金贵.农产品品质学•第2卷.厦门大学出版社,2014,(第1版),第20-21页. * |
| 黄文达.香草植物就要这样玩.科学技术出版社,2016,(第1版),第107页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113712858A (en) | 2021-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111973515B (en) | Bacteriostatic restoration plant extraction composition, preparation method and application thereof | |
| Coopoosamy et al. | Traditional use, antibacterial activity and antifungal activity of crude extract of Aloe excelsa | |
| CN111529470B (en) | Compound acne-removing and allergy-relieving gel and preparation method thereof | |
| KR100712249B1 (en) | Oily to acne skin cosmetics composite containing oriental herb extract and manufacturing method thereof | |
| CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
| CN113274455A (en) | Traditional Chinese medicine composition and application thereof | |
| KR102330277B1 (en) | Cosmetics composition comprising centella asiatica extracts | |
| Tofiq et al. | Wound healing activities of Moringa oleifera leaves extract cultivated in Kurdistan region-Iraq. | |
| KR20160050527A (en) | Composition of cosmetics for anti-wrinkle containing Ulva pertusa Kjellman extracts | |
| CN113712858B (en) | Preparation and application of antibacterial and anti-inflammatory plant extract composition | |
| KR20110130184A (en) | An extract of cudrania tricuspidata and a cosmetic composition containing the extract with anti-acne effect | |
| CN116492385A (en) | Compound essential oil for repairing skin and pharmaceutical composition containing compound essential oil | |
| CN109364290A (en) | A kind of Lavender liposome liquid adhesive bandage and preparation method thereof | |
| CN115414308A (en) | Acne removing composition as well as preparation method and application thereof | |
| JP2010202604A (en) | Agent for normalization of skin indigenous microorganism, method for normalization of skin indigenous microorganism and dermatological external preparation or cosmetic using the same, and process for their productions | |
| CN111744054B (en) | Antibacterial wound surface dressing capable of promoting healing and preparation method thereof | |
| KR20090075950A (en) | Therapeutical compositions for obstinate atopic dermatitis | |
| KR20190012818A (en) | Composition for External Use Comprising Chionanthus Retusus Extracts for Alleviating Skin Irritation or Skin Inflammation | |
| KR20130143241A (en) | Composite natural antiseptics from forsythia suspensa vahl, leonurus sibiricus l., crataegi fructus and akebia quinata decaisne, cosmetic compositions containing them | |
| KR20210096436A (en) | Shampoo Composition and manufacturing mehtod thereof | |
| KR20210065591A (en) | Functional cosmetic composition comprising buah merah fruit oil and clove flower extract as active ingredients | |
| Usman et al. | Preliminary anti-oxidant profile of selected medicinal plants of Pakistan | |
| EP2841079B1 (en) | New compositions for the treatment of chronic ulcers | |
| CN115251093B (en) | Disinfectant composition containing aromatic Chinese medicinal essential oil and guarana extract and preparation method thereof | |
| KR102216902B1 (en) | Skin care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |